The discovery of the proprotein convertase subtilisin/kexin type 9 (PCSK9) and the protein’s ability to regulate LDL-receptor (LDL-R) numbers expressed on hepatocytes made PCSK9 a potent target against hypercholesterolemia and resulted in a drug-development surge of various anti-PCSK9 pharmacological modalities (6). Here, LDLR is linked to familial hypercholesterolemia.